In order to reduce hospitalizations and improve the prognosis and the quality of life of CVD patients, especially with heart failure (HF), the recent guidelines [2,3] indicate the need for drug therapy based on four pharmacological “pillars” (Angiotensin-Converting Enzyme inhibitors—ACE inhibitors; Angiotensin Receptor Blocker—ARB; Angiotensin Receptor–Neprilysin Inhibitor—ARNI; mineralocorticoid receptor antagonists—MRA; beta blocker; Sodium–Glucose Cotransporter 2—SGLT2 inhibitors). The gene discussed is ACE; the disease is heart failure.